| Abstract: | This study aimed to explore the correlations between cadherin-17 (CDH17) proteinexpression and the clinicopathological features and prognosis of patients withsporadic gastric cancer (GC). Nine relevant studies of 1,960 patients were identifiedusing electronic database searches supplemented with a manual search in strictaccordance with inclusion and exclusion criteria. Statistical analyses were conductedusing STATA 12.0 statistical software. Relative risks and 95% confidence intervalswere determined, and Z test was used to measure the significance ofthe overall effect size. A total of nine eligible cohort studies were included inthis meta-analysis. The expression of CDH17 in patients with diffuse GC wassignificantly higher than in those with intestinal-type GC. Moreover, the tumor depthof invasion differed significantly between patients with positive CDH17 (CDH17+) andnegative CDH17 (CDH17-) GC. However, there were no significant differences betweenCDH17+ and CDH17- GC patients with respect to tumor node metastasis clinical stages,histological grades, or lymph node metastasis. Despite the differences in invasivedepth, there was no significant difference in 5-year survival rates between CDH17+and CDH17- GC patients. Our meta-analysis provides evidence that CDH17 proteinexpression may be associated with the development of GC, suggesting that CDH17 is animportant biomarker that could be useful for the early diagnosis of GC. However,CDH17 levels do not appear to impact overall survival. |
